Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706639 · ClinicalTrials.gov registry record
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
A clinical trial of Cardiovascular Disease and Williams Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 1,099
- Enrollment target
- 3
- Study locations
NCT02706639 is a study of Cardiovascular Disease and Williams Syndrome that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,099 participants, below the 2,705-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02706639, a study of Cardiovascular Disease and Williams Syndrome, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 1,099 participants
- Enrollment target
- 3
- Study locations
Study Summary
Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome. Haploinsufficiency for these genes leads to the features of the condition, including: * Distinctive facial features; * Characteristic vascular problems including hypertension, focal vascular stenosis, (when present in the aorta this is referred to as SVAS), vascular stiffness and differences in heart rate variability; * Endocrine abnormalities including hypercalcemia, hypothyroidism, and early puberty; * Metabolic concerns with colic and failure to gain weight in infancy and obesity and early glucose intolerance in adulthood; * Characteristic neurocognitive profile comprised of cognitive impairment, high sociality with concurrent social awkwardness, difficulty with visual-spatial tasks, relative strengths in speech, and lack of social fear; * Anxiety and chronic pain in adulthood Most individuals with WS carry the same basic deletion on Chromosome 7q11.23. However, each feature may present as mild or more severe in any given individual. Variation in the presence and severity of these vascular phenotypes remains unexplained. The supravalvar aortic stenosis (SVAS) phenotype is caused by haploinsufficiency for elastin. This can come about due to the WS deletion (as above) or due to heterozygous variation in elastin (ELN) gene itself in this region. When this protein is reduced, connective tissues lose its strength, flexibility, and overall support. When this happens in the aorta, it may cause vascular narrowing that presents as shortness of breath, chest pain, and even heart failure if left untreated. Narrowing also occurs in other vessels especially the pulmonary and renal arteries. Changes in non-vascular elastic tissues such as the skin and lungs also occur. As in WBS, phenotypic variation also occurs in people with ELN gene changes--This variability remains unexplained despit
Conditions Studied
Study Locations (3)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Missouri
- Washington University School of Medicine - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2040-09-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706639
The ClinicalTrials.gov registry entry for NCT02706639 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,099 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,705-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (59% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02706639 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT02706639 about?
NCT02706639 is a clinical study titled "Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank". Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome. Haploinsufficiency for these genes leads to the features of the condition, including: * Distinctive facial fe...
What is the current status of trial NCT02706639?
This trial is currently recruiting. The enrollment target is 1,099 participants. The study started on 2016-05-11. Estimated completion is 2040-09-25.
What conditions does trial NCT02706639 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Williams Syndrome, Supravalvular Aortic Stenosis.
Who is sponsoring clinical trial NCT02706639?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02706639 being conducted?
This trial has 3 study locations across Maryland, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single-tracer Multiparametric PET Imaging
RECRUITING · Early Phase 1
-
WISE CVD - Continuation (WISE HFpEF)
RECRUITING
-
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RECRUITING · NA
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)
RECRUITING
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.